Related Experiment Video
Updated: May 2, 2026
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
6.2K
Changes in biologic features between primary and recurrent or relapsed breast cancers.
S Al-Awadi1, S Thuruthel2, K Yamini1
1Department of Medical Oncology, Kuwait Cancer Control Centre, Kuwait.
The Gulf Journal of Oncology
|March 11, 2014
Summary
Breast cancer patients often experience changes in estrogen receptor (ER) and progesterone receptor (PR) status, with less frequent alterations in Her2. Re-biopsy at recurrence is recommended to guide treatment.
Area of Science:
- Oncology
- Medical Research
Background:
- Breast cancer is a heterogeneous disease.
- Hormone receptor (ER, PR) and Her2 status can change between primary and metastatic sites.
- Understanding these receptor changes is crucial for effective treatment.
Purpose of the Study:
- To evaluate changes in ER, PR, and Her2 receptor status in Kuwait's breast cancer population.
- To determine the frequency of these biological feature alterations during disease progression.
Main Methods:
- Retrospective study of 70 breast cancer patients (2009-2012).
- Analysis of biological features between primary and recurrent disease.
- Statistical comparison using chi-square and Kaplan-Meier survival analysis.
Main Results:
- ER positivity decreased from 61.4% to 58.6% (28.5% overall change).
- PR positivity decreased from 61.4% to 44.3% (25.7% overall change).
- Her2 positivity increased, with 5.7% overall change in status.
Conclusions:
- Biological markers in breast cancer patients change during disease course.
- Hormone receptor changes are more common than Her2 changes.
- Consider re-biopsy at relapse for accurate receptor status assessment.
Related Concept Videos
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:40Cancer Stem Cells and Tumor Maintenance
4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:30Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K